EN DE

Xi'an International Medical Investment Company (000516) Fair Value & Analysis

Healthcare · CN · Market cap 9.0B CNY

XA Xi'an International Medical Investment Company 000516 · SHE
Price¥4.25
Fair Value¥0.8300
Upside-80.5%
Quality54/100
Watch Xi'an International Medical Investment Company for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -6.3% net margin
Moderate debt · generates free cash flow
Trails peers (4/12)
Narrow moat 11/100
Evidence: Medium Range ¥0.3100 – ¥1.35 Share as image

Fair value as of: Jul 21, 2026

From 11 valuation models · updated 20 days ago

Fair value updated Jul 21, 2026, revised from ¥0.9300 to ¥0.8300 (−10.8%) since Jun 25, 2026. Share price +8.7% over the past month.

A solid business, but screening 80% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥1.35). The favourable scenario is already priced in.
  • The model range is unusually wide (¥0.3100 to ¥1.35). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥21.13 ¥3.86 Fair Value ¥0.8300 Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range ¥3.86 – ¥21.13 · fair‑value band ¥0.3100 – ¥1.35 · the ¥4.25 price screens above the ¥0.8300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Xi'an International Medical Investment Company (000516) currently trades at ¥4.25, while our model-based Fair Value estimate is ¥0.8300, implying the stock looks roughly 80.5% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Xi'an International Medical Investment Company generated revenue of 4.0B CNY at a net margin of -6.3%. Revenue declined 2.8% year over year. It earns a return on equity of -11.5%. Net debt stands at 2.8B CNY. Fundamentals as of Jul 21, 2026

Our scenario range runs from ¥0.3100 (bear case) to ¥1.35 (bull case); at ¥4.25, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -80%, 000516 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF ¥4.56 ¥8.06 ¥13.54 80
Rev-Margin DCF ¥2.03 ¥3.38 ¥5.09 74
EV/EBITDA ¥0.7700 ¥1.29 ¥1.81 54
All 11 models by family
DCF Models
FCF DCF ¥4.58 ¥8.36 ¥14.47 38
Owner Earnings ¥0.2300 ¥0.9100 31
5Y Revenue Exit ¥2.03 ¥3.33 ¥4.97 39
5Y EBITDA Exit ¥1.98 ¥3.24 ¥4.69 41
10Y Revenue Exit ¥2.84 ¥4.33 ¥6.36 36
10Y EBITDA Exit ¥2.86 ¥4.26 ¥6.14 37
Multiples
EV/EBITDA ¥0.7700 ¥1.29 ¥1.81 54
EV/Revenue ¥0.7400 ¥1.40 ¥2.05 43
Asset-Based
NCAV (Graham) ¥0.7400 ¥0.9900 ¥1.48 50
Growth DCF
Growth DCF ¥4.56 ¥8.06 ¥13.54 80
Rev-Margin DCF ¥2.03 ¥3.38 ¥5.09 74

Widest divergence: Growth DCF (¥3.38) versus Asset-Based (¥0.9900). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) 4.0B CNY
Revenue growth (YoY) -2.8%
Net margin -6.3%
Return on equity -11.5%
Free cash flow 1.0B CNY FY2025
Operating margin -4.2%
More key figures
EPS (TTM) ¥-0.1100
Net debt 2.8B CNY FY2025

Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 54 · Market factors (momentum, volatility) 36

Profitability 8
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 91
Earnings quality: real cash, not paper profit
Fin. Strength 27
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 23
Price trend over the last 3–12 months (market factor)
52W Momentum 16
Distance to the 52-week high (market factor)
Net Issuance 92
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Xi'an International Medical Investment Company Limited provides healthcare services. It operates hospitals and medical centers. It also engages in insurance broking, tourism, and pharmaceutical production business. Xi'an International Medical Investment Company Limited was formerly known as Xi'an Kaiyuan Investment Group Co., Ltd.

Full company description

Xi'an International Medical Investment Company Limited provides healthcare services. It operates hospitals and medical centers. It also engages in insurance broking, tourism, and pharmaceutical production business. Xi'an International Medical Investment Company Limited was formerly known as Xi'an Kaiyuan Investment Group Co., Ltd. and changed its name to Xi'an International Medical Investment Company Limited in January 2015. The company was founded in 1986 and is based in Xi'an, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Xi'an International Medical Investment Company reported revenue of ¥4.1B in FY2025 versus ¥2.9B in FY2021, a compound +8.7%/yr. Reported net income was −¥313M in FY2025.

Growth Quality 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
4.1B CNY
Latest YoY
−15.4%
Avg. growth/yr (3Y)
+14.5%
Avg. growth/yr (5Y)
+20.5%
Avg. growth/yr (34Y)
+14.7%
Revenue +8.7%/yr
FY21 ¥2.9B
FY22 ¥2.7B
FY23 ¥4.6B
FY24 ¥4.8B
FY25 ¥4.1B
Net income
FY21 −¥822M
FY22 −¥1.2B
FY23 −¥368M
FY24 −¥254M
FY25 −¥313M

000516 screens 80% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Xi'an International Medical Investment Company Fair Value". https://www.fairvalue-calculator.com/stock/000516

Peer Group

Medical Care Facilities · 262 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 54 · Below median
Fair Value upside −81% · Bottom 25%
Return on assets -1% · Bottom 25%
Net margin (TTM) -6% · Bottom 25%
Operating margin (TTM) -4% · Bottom 25%
Revenue growth -3% · Bottom 25%
Debt / equity 0.65× · Higher than 75% of peers

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.40× · Cheaper than 75% of peers
P/S (TTM) 0.33× · Cheaper than 75% of peers
P/FCF 1.3× · Cheaper than median
EV/EBITDA 7.3× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 22
FUTURE 0 · sector 24
PAST 0 · sector 30
HEALTH 67 · sector 90
DIVIDEND 0 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Xi'an International Medical Investment Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Xi'an International Medical Investment Company (000516) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of ¥0.8300 versus a price of ¥4.25, about −80% (overvalued).
What is the fair value of 000516?
Our model-based fair value for Xi'an International Medical Investment Company is ¥0.8300 (as of Jul 21, 2026), built from audited fundamentals. The current price is ¥4.25.
What is the quality score of 000516?
Xi'an International Medical Investment Company has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Xi'an International Medical Investment Company (000516)?
Xi'an International Medical Investment Company reported trailing-twelve-month revenue of about 4.0B CNY (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 000516?
The net profit margin of Xi'an International Medical Investment Company is about -6.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Xi'an International Medical Investment Company and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.